

Chloe Orkin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12134468/publications.pdf>

Version: 2024-02-01

104
papers

7,319
citations

61945

43
h-index

56687

83
g-index

105
all docs

105
docs citations

105
times ranked

7301
citing authors

#	ARTICLE	IF	CITATIONS
1	The hepatitis C cascade of care in HIV/hepatitis C virus coinfecting individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435.	1.0	8
2	Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir. <i>HIV Medicine</i> , 2022, 23, 362-370.	1.0	2
3	Editorial: Is it time to implement injectable antiretroviral treatments globally?. <i>Current Opinion in HIV and AIDS</i> , 2022, 17, 119-120.	1.5	0
4	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naïve Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial. <i>Clinical Infectious Diseases</i> , 2021, 73, 33-42.	2.9	38
5	Changes in weight and BMI with first-line doravirine-based therapy. <i>Aids</i> , 2021, 35, 91-99.	1.0	25
6	Long-acting injectable HIV therapies: the next frontier. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 8-15.	1.3	11
7	Long-acting injectable HIV therapies: the next frontier: Republication. <i>Current Opinion in HIV and AIDS</i> , 2021, 16, 98-105.	1.5	4
8	Redressing Gender Imbalance in Leadership in Academic Medicine. <i>Academic Medicine</i> , 2021, 96, 480-480.	0.8	0
9	Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. <i>Lancet HIV</i> , 2021, 8, e185-e196.	2.1	80
10	Weight Change Following Antiretroviral Therapy Switch in People With Viral Suppression: Pooled Data from Randomized Clinical Trials. <i>Clinical Infectious Diseases</i> , 2021, 73, 1440-1451.	2.9	55
11	Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK. <i>HIV Medicine</i> , 2021, 22, 631-640.	1.0	9
12	Gender disparities in coronavirus disease 2019 clinical trial leadership. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1007-1010.	2.8	22
13	Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 393-398.	0.9	4
14	Initiation of long-acting cabotegravir plus rilpivirine as direct-to-injection or with an oral lead-in in adults with HIV-1 infection: week 124 results of the open-label phase 3 FLAIR study. <i>Lancet HIV</i> , 2021, 8, e668-e678.	2.1	55
15	Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. <i>Aids</i> , 2021, 35, 759-767.	1.0	7
16	69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks. <i>Open Forum Infectious Diseases</i> , 2021, 8, S46-S46.	0.4	0
17	Once-daily Doravirine for Initial Treatment of Adults Living With Human Immunodeficiency Virus-1: An Integrated Safety Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1336-1343.	2.9	6
18	Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naïve Adults: An Integrated Efficacy Analysis. <i>Clinical Infectious Diseases</i> , 2020, 70, 1344-1352.	2.9	9

#	ARTICLE	IF	CITATIONS
19	Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. <i>Clinical Infectious Diseases</i> , 2020, 71, 1379-1389.	2.9	436
20	Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , 2020, 34, 707-718.	1.0	30
21	Emergent Resistance to Dolutegravir Among INSTI-Naïve Patients on First-line or Second-line Antiretroviral Therapy: A Review of Published Cases. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa202.	0.4	25
22	Enrolling pregnant women with HIV into clinical trials. <i>Lancet HIV</i> , 2020, 7, e302-e303.	2.1	2
23	Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. <i>Lancet HIV</i> , 2020, 7, e389-e400.	2.1	70
24	Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 325-330.	0.9	32
25	Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 498-506.	0.9	78
26	Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. <i>New England Journal of Medicine</i> , 2020, 382, 1124-1135.	13.9	232
27	Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. <i>HIV Medicine</i> , 2020, 21, 309-321.	1.0	3
28	Immediate Versus Deferred Switching From a Boosted Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen in Virologically Suppressed Patients With High Cardiovascular Risk or Age ≥50 Years: Final 96-Week Results of the NEAT022 Study. <i>Clinical Infectious Diseases</i> , 2019, 68, 597-606.	2.9	34
29	Efficacy and safety of dolutegravir+rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. <i>Lancet HIV</i> , 2019, 6, e576-e587.	2.1	82
30	Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. <i>Antiviral Research</i> , 2019, 170, 104543.	1.9	32
31	Reply to Lanzafame et al. <i>Clinical Infectious Diseases</i> , 2019, 69, 1832-1833.	2.9	0
32	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: subgroup analyses of the phase 3 EMERALD study. <i>AIDS Research and Therapy</i> , 2019, 16, 23.	0.7	7
33	Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate. <i>Aids</i> , 2019, 33, 1455-1465.	1.0	99
34	Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 746-753.	1.3	7
35	Just another vial?™: a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK. <i>BMJ Open</i> , 2019, 9, e024085.	0.8	9
36	Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz+tenofovir+emtricitabine for HIV. <i>Journal of Virus Eradication</i> , 2019, 5, 204-211.	0.3	6

#	ARTICLE	IF	CITATIONS
37	Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naïve Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 535-544.	2.9	122
38	Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naïve adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. <i>Lancet</i> , The, 2019, 393, 143-155.	6.3	265
39	Uptake of Tenofovir-Based Antiretroviral Therapy among HIV-1/ HBV-Coinfected Patients in the EuroSIDA Study. <i>Antiviral Therapy</i> , 2018, 23, 405-413.	0.6	5
40	Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data. <i>AIDS Research and Therapy</i> , 2018, 15, 11.	0.7	3
41	A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve HIV-1 patients. <i>Aids</i> , 2018, 32, 1431-1442.	1.0	72
42	Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected With Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 1010-1017.	2.9	125
43	Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate. <i>Current Opinion in HIV and AIDS</i> , 2018, 13, 315-319.	1.5	4
44	Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. <i>Lancet HIV</i> , the, 2018, 5, e23-e34.	2.1	83
45	1965. Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients With Chronic Hepatitis C Virus Genotypes 1&6 and Human Immunodeficiency Virus-1 Co-Infection: An Integrated Analysis of Two Phase 3 Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2018, 5, S569-S570.	0.4	0
46	LB1. Doravirine/Lamivudine/Tenofovir DF Continues to Be NonInferior to Efavirenz/Emtricitabine/Tenofovir DF in Treatment-Naïve Adults With HIV-1 Infection: Week 96 Results of the DRIVE-AHEAD Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S759-S759.	0.4	8
47	543. An Integrated Safety Analysis Comparing Once-Daily Doravirine (DOR) to Darunavir+Ritonavir (DRV+r) and Efavirenz (EFV) in HIV-1-Infected, Antiretroviral Therapy (ART)-Naïve Adults. <i>Open Forum Infectious Diseases</i> , 2018, 5, S201-S202.	0.4	1
48	1768. Efficacy and Safety of Switching From Boosted-Protease Inhibitors (bPI) Plus Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) Regimens to the Once Daily (QD), Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Virologically Suppressed, HIV-1-Infected Adults: Week 96 Results of the Phase 3, Randomized, Non-Inferiority EMERALD Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S65-S65.	0.4	1
49	Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. <i>Clinical Infectious Diseases</i> , 2018, 69, 1136-1143.	2.9	5
50	A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. <i>Lancet HIV</i> , the, 2018, 5, e301-e308.	2.1	34
51	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. <i>Lancet HIV</i> , the, 2017, 4, e195-e204.	2.1	64
52	Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. <i>Lancet HIV</i> , the, 2017, 4, e295-e302.	2.1	47
53	Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 75, 226-231.	0.9	72
54	Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. <i>Clinical Infectious Diseases</i> , 2017, 64, 1413-1421.	2.9	66

#	ARTICLE	IF	CITATIONS
55	A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. <i>BMJ Open</i> , 2017, 7, e016494.	0.8	12
56	Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. <i>Lancet</i> , The, 2017, 390, 2063-2072.	6.3	253
57	Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx154.	0.4	14
58	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. <i>HIV Medicine</i> , 2016, 17, s2-s104.	1.0	78
59	Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?. <i>BMJ Open</i> , 2016, 6, e010661.	0.8	14
60	Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy. <i>Aids</i> , 2016, 30, 2617-2624.	1.0	19
61	Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. <i>HIV Medicine</i> , 2016, 17, 368-372.	1.0	7
62	Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 43-52.	4.6	256
63	A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals. <i>PLoS ONE</i> , 2015, 10, e0116297.	1.1	28
64	Should HIV testing week be blood-borne-virus testing week?. <i>Lancet HIV</i> , the, 2015, 2, e510-e511.	2.1	1
65	Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. <i>Lancet</i> , The, 2015, 385, 1098-1106.	6.3	170
66	Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. <i>Journal of Infectious Diseases</i> , 2015, 212, 367-377.	1.9	54
67	Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. <i>Lancet HIV</i> , the, 2015, 2, e319-e327.	2.1	285
68	Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trial. <i>Lancet HIV</i> , the, 2015, 2, e417-e426.	2.1	75
69	NtRTI sparing in patients at risk of bone disease. <i>Lancet HIV</i> , the, 2015, 2, e452-e453.	2.1	0
70	Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. <i>Aids</i> , 2014, 28, 1193-1202.	1.0	453
71	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight.). <i>HIV Medicine</i> , 2014, 15, 1-6.	1.0	101
72	Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2014, 59, 1579-1587.	2.9	63

#	ARTICLE	IF	CITATIONS
73	Opt-out HIV testing in adult critical care units. <i>Lancet, The</i> , 2014, 383, 1460.	6.3	36
74	HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. <i>Aids</i> , 2014, 28, 689-697.	1.0	53
75	Failure to achieve a CD4+ cell count response on combination antiretroviral therapy despite consistent viral load suppression. <i>Aids</i> , 2014, 28, 919-924.	1.0	9
76	Once-daily dolutegravir versus raltegravir in antiretroviral-naïve adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. <i>Lancet, The</i> , 2013, 381, 735-743.	6.3	455
77	Persistence of HIV-1 Transmitted Drug Resistance Mutations. <i>Journal of Infectious Diseases</i> , 2013, 208, 1459-1463.	1.9	92
78	Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1354-9.	1.3	30
79	British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. <i>HIV Medicine</i> , 2013, 14, 1-71.	1.0	43
80	Week 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two Phase III randomized trials. <i>Aids</i> , 2013, 27, 939-950.	1.0	117
81	96-Week Results of Abacavir/Lamivudine versus Tenofovir/Emtricitabine, plus Efavirenz, in Antiretroviral-Naïve, HIV-1-Infected Adults: Assert Study. <i>Antiviral Therapy</i> , 2013, 18, 905-913.	0.6	58
82	Second line protease inhibitor (PI/r) based antiretroviral therapy (ART) after non-nucleoside reverse transcriptase inhibitor (NNRTI) failure: impact of nucleoside (NRTI) backbone. <i>Antiviral Therapy</i> , 2012, 18, 213-219.	0.6	14
83	Disease Progression in HIV-1-Infected Viremic Controllers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 407-416.	0.9	28
84	HIV Status Does Not Influence Outcome in Patients With Classical Hodgkin Lymphoma Treated With Chemotherapy Using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the Highly Active Antiretroviral Therapy Era. <i>Journal of Clinical Oncology</i> , 2012, 30, 4111-4116.	0.8	145
85	British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. <i>HIV Medicine</i> , 2012, 13, 1-6.	1.0	149
86	Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. <i>Journal of Clinical Virology</i> , 2011, 52, 367-369.	1.6	18
87	Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. <i>BMJ: British Medical Journal</i> , 2011, 343, d6016-d6016.	2.4	282
88	Outcomes in the First Year after Initiation of First-Line Haart among Heterosexual Men and Women in the Uk Chic Study. <i>Antiviral Therapy</i> , 2011, 16, 805-814.	0.6	36
89	Detection of drug resistance mutations at low plasma HIV-1 RNA load in a European multicentre cohort study. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1886-1896.	1.3	56
90	Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. <i>Aids</i> , 2010, 24, 851-856.	1.0	54

#	ARTICLE	IF	CITATIONS
91	Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals. PLoS ONE, 2010, 5, e8805.	1.1	405
92	Comparison of Changes in Bone Density and Turnover with Abacavir+Lamivudine versus Tenofovir+Emtricitabine in HIV-1-Infected Adults: 48-Week Results from the ASSERT Study. Clinical Infectious Diseases, 2010, 51, 963-972.	2.9	370
93	Factors influencing lopinavir and atazanavir plasma concentration. Journal of Antimicrobial Chemotherapy, 2010, 65, 129-137.	1.3	23
94	Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: clade C infection results in a stronger and broader humoral immune response than clade B infection. Journal of General Virology, 2010, 91, 2794-2803.	1.3	22
95	Data linkage reduces loss to follow-up in an observational HIV cohort study. Journal of Clinical Epidemiology, 2010, 63, 1101-1109.	2.4	25
96	A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 562-568.	0.9	59
97	CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica, 2009, 94, 875-880.	1.7	81
98	Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: multicentre cohort study. Aids, 2008, 22, 1943-1950.	1.0	16
99	Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Associated Burkitt's Lymphoma (BL). Blood, 2008, 112, 3612-3612.	0.6	0
100	Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication. Antiviral Therapy, 2008, 13, 675-85.	0.6	47
101	Factors Influencing Efavirenz and Nevirapine Plasma Concentration: Effect of Ethnicity, Weight and Co-Medication. Antiviral Therapy, 2008, 13, 675-685.	0.6	90
102	Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. Aids, 2007, 21, 1423-1430.	1.0	30
103	Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet, The, 2007, 370, 1923-1928.	6.3	59
104	A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	28